This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2020-2022.
Location History:
- Frederick, MD (US) (2020 - 2022)
- Rockville, MD (US) (2022)
Company Filing History:
Years Active: 2020-2022
Title: The Innovations of Tony Navas
Introduction
Tony Navas is a notable inventor based in Frederick, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. With a total of 3 patents to his name, Navas has demonstrated a commitment to advancing medical science through innovative solutions.
Latest Patents
Navas's latest patents include groundbreaking work on Anti-CD133 monoclonal antibodies and related compositions and methods. This patent focuses on monoclonal antibodies that possess advantageous properties, along with products, compositions, and kits that incorporate these antibodies. Additionally, it outlines methods for making these monoclonal antibodies and their applications in analytical, diagnostic, and therapeutic settings. Another significant patent is the Anti-pY1235-MET immunological binding reagent, which describes methods and compositions for assaying the presence or absence of pY1235-MET or its fragments.
Career Highlights
Tony Navas works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His role in this esteemed organization highlights his dedication to public health and innovation. Navas's work has the potential to impact various medical fields, particularly in diagnostics and therapeutics.
Collaborations
Some of his notable coworkers include Thomas D. Pfister and Robert J. Kinders. Their collaboration has likely contributed to the success of Navas's innovative projects and patents.
Conclusion
Tony Navas is a distinguished inventor whose work in monoclonal antibodies is paving the way for advancements in medical diagnostics and therapies. His contributions are invaluable to the scientific community and hold promise for future innovations.